CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 77 filers reported holding CUE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,714 | +23.8% | 5,528 | +96.5% | 0.00% | – |
Q2 2023 | $10,267 | +71.1% | 2,813 | -3.2% | 0.00% | – |
Q3 2022 | $6,000 | -53.8% | 2,906 | -47.4% | 0.00% | – |
Q2 2022 | $13,000 | -18.8% | 5,522 | +68.7% | 0.00% | – |
Q1 2022 | $16,000 | -40.7% | 3,273 | +37.9% | 0.00% | – |
Q4 2021 | $27,000 | -34.1% | 2,373 | -14.9% | 0.00% | -100.0% |
Q3 2021 | $41,000 | -31.7% | 2,787 | -45.7% | 0.00% | -50.0% |
Q2 2021 | $60,000 | +275.0% | 5,131 | +299.0% | 0.00% | – |
Q1 2021 | $16,000 | -61.9% | 1,286 | -61.6% | 0.00% | -100.0% |
Q4 2020 | $42,000 | +133.3% | 3,349 | +183.6% | 0.00% | – |
Q3 2020 | $18,000 | -90.4% | 1,181 | -84.6% | 0.00% | -100.0% |
Q2 2020 | $188,000 | +4600.0% | 7,650 | +1426.9% | 0.01% | – |
Q3 2019 | $4,000 | -75.0% | 501 | -75.7% | 0.00% | -100.0% |
Q1 2019 | $16,000 | -84.3% | 2,065 | -90.5% | 0.00% | -85.7% |
Q4 2018 | $102,000 | +175.7% | 21,641 | +430.5% | 0.01% | +133.3% |
Q3 2018 | $37,000 | +825.0% | 4,079 | +1136.1% | 0.00% | – |
Q2 2018 | $4,000 | -33.3% | 330 | -20.1% | 0.00% | -100.0% |
Q1 2018 | $6,000 | – | 413 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Prosight Management, LP | 1,545,573 | $3,447,000 | 1.85% |
P.A.W. CAPITAL CORP | 200,000 | $446,000 | 0.67% |
SANDERS MORRIS HARRIS LLC | 848,048 | $2,020,000 | 0.50% |
Monaco Asset Management SAM | 458,851 | $1,023,000 | 0.39% |
Bleichroeder LP | 555,000 | $1,238,000 | 0.26% |
APOGEM CAPITAL LLC | 110,614 | $247,000 | 0.25% |
Slate Path Capital LP | 1,483,619 | $3,308,000 | 0.22% |
Voss Capital, LLC | 200,000 | $446,000 | 0.13% |
Robertson Stephens Wealth Management, LLC | 478,500 | $1,067,000 | 0.11% |
CARLSON CAPITAL L P | 535,000 | $1,193,000 | 0.09% |